Receptor tyrosine kinases in osteosarcoma: Not just the usual suspects

Advances in Experimental Medicine and Biology

Volumn 804, Issue , 2015, Pages 66-74

  Rettew, Ashley N ^a   Getty, Patrick J ^a,b   Greenfield, Edward M ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Axl; EphB2; FGFR2; IGF 1R; Osteosarcoma; Phosphoproteomic screen; Receptor tyrosine kinases; Ret; Targeted therapy

Indexed keywords

ABELSON KINASE; CAVEOLIN 1; DASATINIB; EPHRIN RECEPTOR B2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; PROTEIN RET; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SOMATOMEDIN C RECEPTOR; SORAFENIB; ANTINEOPLASTIC AGENT; AXL RECEPTOR TYROSINE KINASE; EPHB2 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; RET PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; DRUG TARGETING; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; INTRACELLULAR SIGNALING; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; NONHUMAN; OLIGOMERIZATION; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; BONE TUMOR; CELL DIFFERENTIATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; OSTEOSARCOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPHB2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84926650261     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-04843-7_3     Document Type: Article

References (137)

1. Hubbard SR, Till JH (2000) Protein tyrosine kinase structure and function. Annu Rev Biochem 69: 373-398
2. Manning G, Whyte DB, Martinez R et al (2002) The protein kinase complement of the human genome. Science 298 (5600): 1912-1934
3. Chong PK, Lee H, Kong JW et al (2008) Phosphoproteomics, oncogenic signaling and cancer research. Proteomics 8 (21): 4370-4382
4. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141 (7): 1117-1134
5. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4 (5): 361-370
6. Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109 (3): 275-282
7. Hubbard SR, Miller WT (2007) Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 19 (2): 117-123
8. Bae YS, Kang SW, Seo MS et al (1997) Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 272 (1): 217-221
9. Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353 (2): 172-187
10. Kim H, Gillis LC, Jarvis JD et al (2011) Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events. BMC Cancer 11: 528
11. Kurzrock R, Kantarjian HM, Druker BJ et al (2003) Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Annal Int Med 138 (10): 819-830
12. Rowley JD (1973) Chromosomal patterns in myelocytic leukemia. N Engl J Med 289 (4): 220-221
13. Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (5405): 290-293
14. Kim DW, Hwang JH, Suh JM et al (2003) RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositidedependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1. Mol Endocrinol 17 (7): 1382-1394
15. May WA, Lessnick SL, Braun BS et al (1993) The Ewing’s sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 13 (12): 7393-7398
16. De Vito C, Riggi N, Suva ML et al (2011) Let-7a is a direct EWS-FLI-1 target implicated in Ewing’s sarcoma development. PLoS One 6 (8): e23592
17. Nishikawa R, Ji XD, Harmon RC et al (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91 (16): 7727-7731
18. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10 (2): 116-129
19. Zwick E, Bange J, Ullrich A (2002) Receptor tyrosine kinases as targets for anticancer drugs. Trend Mol Med 8 (1): 17-23
20. Singh AB, Harris RC (2005) Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 17 (10): 1183-1193
21. Miyamoto S, Nakamura M, Yano K et al (2007) Matrix metalloproteinase-7 triggers the matricrine action of insulin-like growth factor-II via proteinase activity on insulin-like growth factor binding protein 2 in the extracellular matrix. Cancer Sci 98 (5): 685-691
22. Baselga J (2006) Targeting tyrosine kinases in cancer: the second wave. Science 312 (5777): 1175-1178
23. Noble ME, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303 (5665): 1800-1805
24. Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9 (1): 28-39
25. Fabbro D, Cowan-Jacob SW, Mobitz H et al (2012) Targeting cancer with small-molecularweight kinase inhibitors. Methods Mol Biol 795: 1-34
26. Adrian FJ, Ding Q, Sim T et al (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2 (2): 95-102
27. Hudis CA (2007) Trastuzumab-Mechanism of action and use in clinical practice. N Engl J Med 357 (1): 39-51
28. Lambrechts D, Lenz HJ, de Haas S et al (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31 (9): 1219-1230
29. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (17): 1757-1765
30. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (6): 567-578
31. Sierra JR, Cepero V, Giordano S (2010) Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 9: 75
32. Kobayashi S, Ji H, Yuza Y et al (2005) An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65 (16): 7096-7101
33. Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (3): e73
34. Burrow S, Andrulis IL, Pollak M et al (1998) Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 69 (1): 21-27
35. Benini S, Baldini N, Manara MC et al (1999) Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer 80 (4): 581-588
36. Hughes DP, Thomas DG, Giordano TJ et al (2006) Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer 46 (5): 614-623
37. Charity RM, Foukas AF, Deshmukh NS et al (2006) Vascular endothelial growth factor expression in osteosarcoma. Clin Orthop Relat Res 448: 193-198
38. Ferracini R, Di Renzo MF, Scotlandi K et al (1995) The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10 (4): 739-749
39. Lee YH, Tokunaga T, Oshika Y et al (1999) Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 35 (7): 1089-1093
40. Sulzbacher I, Birner P, Trieb K et al (2003) Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 16 (1): 66-71
41. Fukuda T, Ichimura E, Shinozaki T et al (1998) Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 48 (10): 757-762
42. Gorlick R, Huvos AG, Heller G et al (1999) Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17 (9): 2781-2788
43. Handa A, Tokunaga T, Tsuchida T et al (2000) Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma. Int J Oncol 17 (2): 291-295
44. Kaya M, Wada T, Kawaguchi S et al (2002) Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 86 (6): 864-869
45. Oda Y, Yamamoto H, Tamiya S et al (2006) CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 19 (5): 738-745
46. Onda M, Matsuda S, Higaki S et al (1996) ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77 (1): 71-78
47. Luu HH, Kang Q, Park JK et al (2005) An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Meta 22 (4): 319-329
48. Jia SF, Worth LL, Kleinerman ES (1999) A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Meta 17 (6): 501-506
49. Rettew AN, Young ED, Lev DC et al (2012) Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis 1 (e34): 1-9
50. Kolb EA, Gorlick R (2009) Development of IGF-IR Inhibitors in Pediatric Sarcomas. Curr Oncol Rep 11 (4): 307-313
51. Larsson O, Girnita A, Girnita L (2005) Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92 (12): 2097-2101
52. Kappel CC, Velez-Yanguas MC, Hirschfeld S et al (1994) Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 54 (10): 2803-2807
53. Wang YH, Wang ZX, Qiu Y et al (2009) Lentivirus-mediated RNAi knockdown of insulinlike growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells. Mol Cell Biochem 327 (1-2): 257-266
54. Dong J, Demarest SJ, Sereno A et al (2010) Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther 9 (9): 2593-2604
55. Kolb EA, Gorlick R, Houghton PJ et al (2008) Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50 (6): 1190-1197
56. Kolb EA, Kamara D, Zhang W et al (2010) R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 55 (1): 67-75
57. Wang Y, Lipari P, Wang X et al (2010) A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther 9 (2): 410-418
58. Pollak M, Sem AW, Richard M et al (1992) Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 84 (12): 966-971
59. Messerschmitt PJ, Rettew AN, Brookover RE et al (2008) Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res 466 (9): 2168-2175
60. Bagatell R, Herzog CE, Trippett TM et al (2011) Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res 17 (3): 611-619
61. Kolb EA, Gorlick R, Lock R et al (2011) Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 56 (4): 595-603
62. Kuijjer ML, Peterse EF, van den Akker BE et al (2013) IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer 13: 245
63. Desai J, Solomon J, Davis ID et al (2010) Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors. In: ASCO Annual Meeting Proceedings, 2010, p 3104
64. Houghton PJ, Morton CL, Gorlick R et al (2010) Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 54 (7): 921-926
65. Linger RM, Keating AK, Earp HS et al (2008) TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100: 35-83
66. Varnum BC, Young C, Elliott G et al (1995) Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 373 (6515): 623-626
67. Verma A, Warner SL, Vankayalapati H et al (2011) Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 10 (10): 1763-1773
68. Bellosta P, Costa M, Lin DA et al (1995) The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol 15 (2): 614-625
69. Korshunov VA (2012) Axl-dependent signalling: a clinical update. Clin Sci 122 (8): 361-368
70. Linger RM, Keating AK, Earp HS et al (2010) Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Exp Opin Therap Targ 14 (10): 1073-1090
71. Rankin EB, Fuh KC, Taylor TE et al (2010) AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res 70 (19): 7570-7579
72. Holland SJ, Pan A, Franci C et al (2010) R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 70 (4): 1544-1554
73. Linger RM, Cohen RA, Cummings CT et al (2012) Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human nonsmall cell lung cancer. Oncogene 32 (29): 3420-3431
74. Liu L, Greger J, Shi H et al (2009) Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 69 (17): 6871-6878
75. Hong J, Peng D, Chen Z et al (2013) ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. Cancer Res 73 (1): 331-340
76. Keating AK, Kim GK, Jones AE et al (2010) Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther 9 (5): 1298-1307
77. Huang F, Hurlburt W, Greer A et al (2010) Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res 70 (18): 7221-7231
78. Zhang Z, Lee JC, Lin L et al (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44 (8): 852-860
79. Rochlitz C, Lohri A, Bacchi M et al (1999) Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 13 (9): 1352-1358
80. Koorstra JB, Karikari CA, Feldmann G et al (2009) The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 8 (7): 618-626
81. Shieh YS, Lai CY, Kao YR et al (2005) Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7 (12): 1058-1064
82. Gjerdrum C, Tiron C, Hoiby T et al (2010) Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 107 (3): 1124-1129
83. Fernebro J, Francis P, Eden P et al (2006) Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma. Int J Cancer 118 (5): 1165-1172
84. Peng T, Zhang P, Liu J et al (2011) An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest 91 (3): 392-403
85. Barretina J, Caponigro G, Stransky N et al (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (7391): 603-607
86. Hoffman A, Ghadimi MP, Demicco EG et al (2013) Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. Cancer 119 (10): 1868-1877
87. Nakano T, Tani M, Ishibashi Y et al (2003) Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Meta 20 (7): 665-674
88. Zhang Y, Tang YJ, Man Y et al (2013) Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis. Int J Immunopathol Pharmacol 26 (1): 179-188
89. Choy E, Hornicek F, MacConaill L et al (2012) High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer 118 (11): 2905-2914
90. Seo JS, Ju YS, Lee WC et al (2012) The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22 (11): 2109-2119
91. Bai Y, Li J, Fang B et al (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72 (10): 2501-2511
92. Han J, Tian R, Yong B et al (2013) Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients. Biochem Biophys Res Commun 435 (3): 493-500
93. Alvarez H, Montgomery EA, Karikari C et al (2010) The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther 10 (10): 1009-1018
94. Cerchia L, Esposito CL, Camorani S et al (2012) Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther 20 (12): 2291-2303
95. Pasquale EB (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10 (3): 165-180
96. Barco R, Hunt LB, Frump AL et al (2007) The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway. Mol Biol Cell 18 (10): 4003-4012
97. Surawska H, Ma PC, Salgia R (2004) The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15 (6): 419-433
98. Mao W, Luis E, Ross S et al (2004) EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res 64 (3): 781-788
99. Fritsche-Guenther R, Noske A, Ungethum U et al (2010) De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway. Histopathology 57 (6): 836-850
100. Varelias A, Koblar SA, Cowled PA et al (2002) Human osteosarcoma expresses specific ephrin profiles: implications for tumorigenicity and prognosis. Cancer 95 (4): 862-869
101. Koolpe M, Burgess R, Dail M et al (2005) EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem 280 (17): 17301-17311
102. Noberini R, Lamberto I, Pasquale EB (2012) Targeting Eph receptors with peptides and small molecules: progress and challenges. Semin Cell Dev Biol 23 (1): 51-57
103. Hingorani P, Zhang W, Gorlick R et al (2009) Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res 15 (10): 3416-3422
104. Kelleher FC, O’Sullivan H, Smyth E et al (2013) Fibroblast growth factor receptors, developmental corruption and malignant disease. Carcinogenesis 34 (10): 2198-2205
105. Mirabello L, Yu K, Berndt SI et al (2011) A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer 11 (1): 209
106. Sadikovic B, Yoshimoto M, Chilton-MacNeill S et al (2009) Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet 18 (11): 1962-1975
107. Entz-Werle N, Lavaux T, Metzger N et al (2007) Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis. Neoplasia 9 (8): 678-688
108. Baird K, Davis S, Antonescu CR et al (2005) Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 65 (20): 9226-9235
109. Henderson SR, Guiliano D, Presneau N et al (2005) A molecular map of mesenchymal tumors. Gen Biol 6 (9): R76
110. Datsis GA, Berdiaki A, Nikitovic D et al (2011) Parathyroid hormone affects the fibroblast growth factor-proteoglycan signaling axis to regulate osteosarcoma cell migration. FEBS J 278 (19): 3782-3792
111. Singh D, Chan JM, Zoppoli P et al (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337 (6099): 1231-1235
112. Crose LE, Etheridge KT, Chen C et al (2012) FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 18 (14): 3780-3790
113. Terai H, Soejima K, Yasuda H et al (2013) Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res 11 (7): 759-767
114. Oliveras-Ferraros C, Cufi S, Queralt B et al (2012) Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. Br J Cancer 106 (8): 1406-1414
115. Guagnano V, Kauffmann A, Wohrle S et al (2012) FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2 (12): 1118-1133
116. Grigoriadis A, Patino-Garcia A, Zandueta C et al (2010) The role of FGFR signaling in osteosarcoma progression and metastasis. In: 16th annual meeting of the Connective Tissue Oncology Society, Paris, France, 2010, pp 155-156
117. Glen H, Mason S, Patel H et al (2011) E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer 11: 309
118. Nikiforov YE (2002) RET/PTC rearrangement in thyroid tumors. Endoc Pathol 13 (1): 3-16
119. Cockburn JG, Richardson DS, Gujral TS et al (2010) RET-mediated cell adhesion and migration require multiple integrin subunits. J Clin Endocrinol Metab 95 (11): E342-E346
120. Gil Z, Cavel O, Kelly K et al (2010) Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J Natl Cancer Inst 102 (2): 107-118
121. Tang JZ, Kong XJ, Kang J et al (2010) Artemin-stimulated progression of human non-small cell lung carcinoma is mediated by BCL2. Mol Cancer Ther 9 (6): 1697-1708
122. Cheng H, Dodge J, Mehl E et al (2009) Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. Hum Pathol 40 (9): 1244-1251
123. Wolfesberger B, Tonar Z, Gerner W et al (2010) The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line. Res Vet Sci 88 (1): 94-100
124. Pignochino Y, Grignani G, Cavalloni G et al (2009) Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 8: 118
125. Pignochino Y, Dell’Aglio C, Basirico M et al (2013) The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res 19 (8): 2117-2131
126. Mross K, Frost A, Steinbild S et al (2012) A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18 (9): 2658-2667
127. Grignani G, Palmerini E, Dileo P et al (2012) A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 23 (2): 508-516
128. Coltella N, Manara MC, Cerisano V et al (2003) Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J 17 (9): 1162-1164
129. Sampson ER, Martin BA, Morris AE et al (2011) The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res 26 (6): 1283-1294
130. Patane S, Avnet S, Coltella N et al (2006) MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 66 (9): 4750-4757
131. Cantiani L, Manara MC, Zucchini C et al (2007) Cavelolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res 67 (16): 7675-7685
132. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100 (1): 57-70
133. Forbes SA, Bindal N, Bamford S et al (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39 (Database issue): D945-D950
134. Stommel JM, Kimmelman AC, Ying H et al (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318 (5848): 287-290
135. Yu L, Saile K, Swartz CD et al (2008) Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med 14 (5-6): 264-275
136. Davis LE, Hofmann NE, Li G et al (2013) A case study of personalized therapy for osteosarcoma. Pediatr Blood Cancer 60 (8): 1313-1319
137. Xu AM, Huang PH (2010) Receptor tyrosine kinase coactivation networks in cancer. Cancer Res 70 (10): 3857-3860